Skip to content

Xencor Inc Sustainability Reports

Xencor, Inc. is a clinical-stage biopharmaceutical company that discovers and develops engineered monoclonal antibodies and biotherapeutic drug candidates. The company utilizes its proprietary XmAb technology platform to optimize antibodies for treating patients with cancer and autoimmune diseases.

Sector: Manufacturing

Country: United States

Exchange: Nasdaq

LEI: 549300V5IF65437JKG30

FIGI: BBG0026ZG4X9

7 reports from 2014 to 2023